在沙特阿拉伯,压力管理干预措施与刺激性肠综合征 (IBS) 的成年人症状严重程度之间的关联
Randa M Alharazi1, Intessar Sultan1, Gharam A Alahmadi2
1Internal Medicine, Ibn Sina National College for Medical Studies, Jeddah, SAU.
Cureus
|March 2, 2026
概括
实施压力管理技术可以显著降低患者的刺激性肠综合征 (IBS) 症状严重程度和感知压力. 这些发现支持将压力减轻纳入IBS护理.
科学领域:
- 胃肠病学 胃肠病学
- 心理学 心理学 心理学
- 公共卫生 公共卫生
背景情况:
- 心理压力是刺激性肠综合征 (IBS) 的关键因素,这是一个常见的功能性胃肠疾病.
- 了解压力管理和IBS症状严重程度之间的联系对于有效的患者护理至关重要.
研究的目的:
- 评估压力管理干预措施与沙特阿拉伯IBS成年人症状严重程度之间的关联.
- 调查IBS,人口统计,生活方式和感知压力水平之间的关系.
主要方法:
- 在沙特阿拉伯对517名被诊断患有IBS的成年人进行了横截面研究.
- 参与者完成了一项基于网络的调查,包括罗马四号标准,IBS症状严重程度量表 (IBS-SSS) 和感知压力量表 (PSS).
- 统计学意义被设定为p<0.05.
主要成果:
- 24%的参与者使用压力管理技术,主要是深呼吸,冥想和.
- 压力管理从业者报告症状严重程度明显降低 (腹痛,张,肠道习惯满意度,日常干扰) 和感知压力.
- 高压力水平在非从业者中更为普遍;性别和生活方式的选择也影响了IBS负担.
结论:
- 压力管理协议与IBS患者的症状严重程度降低和感知压力的降低有关.
- 建议将压力减轻技术整合到全面的IBS护理计划中.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...

